Slingshot Accelerator

Slingshot Therapeutics, also known as the Slingshot Accelerator, is a UK-based venture studio and drug development accelerator founded by Syncona. The company identifies and in-licenses high-potential early-stage drug discovery programs from leading academic institutions, providing the centralized expertise, funding, and operational infrastructure needed to advance them toward clinical readiness. Its current portfolio includes Apini, a small molecule program for inflammatory diseases, and ALTx Therapeutics, which targets the Alternative Lengthening of Telomeres (ALT) pathway in cancer. By bridging the gap between academic research and clinical development, Slingshot aims to efficiently translate scientific breakthroughs into transformative medicines.